Dr Reddy's Laboratories Total Assets 2010-2024 | RDY

Dr Reddy's Laboratories total assets from 2010 to 2024. Total assets can be defined as the sum of all assets on a company's balance sheet.
  • Dr Reddy's Laboratories total assets for the quarter ending June 30, 2024 were $4.984B, a 22.04% increase year-over-year.
  • Dr Reddy's Laboratories total assets for 2024 were $4.65B, a 18.74% increase from 2023.
  • Dr Reddy's Laboratories total assets for 2023 were $3.916B, a 1.45% increase from 2022.
  • Dr Reddy's Laboratories total assets for 2022 were $3.86B, a 6.34% increase from 2021.
Dr Reddy's Laboratories Annual Total Assets
(Millions of US $)
2024 $4,650
2023 $3,916
2022 $3,860
2021 $3,630
2020 $3,081
2019 $3,259
2018 $3,465
2017 $3,390
2016 $3,134
2015 $3,126
2014 $2,837
2013 $2,611
2012 $2,348
2011 $2,133
2010 $1,787
2009 $569
Dr Reddy's Laboratories Quarterly Total Assets
(Millions of US $)
2024-06-30 $4,984
2024-03-31 $4,650
2023-12-31 $4,482
2023-09-30 $4,178
2023-06-30 $4,084
2023-03-31 $3,916
2022-12-31 $3,739
2022-09-30 $3,576
2022-06-30 $3,746
2022-03-31 $3,860
2021-12-31 $3,798
2021-09-30 $3,760
2021-06-30 $3,743
2021-03-31 $3,630
2020-12-31 $3,456
2020-09-30 $3,445
2020-06-30 $3,326
2020-03-31 $3,081
2019-12-31 $3,054
2019-09-30 $3,311
2019-06-30 $3,295
2019-03-31 $3,259
2018-12-31 $3,258
2018-09-30 $3,229
2018-06-30 $3,372
2018-03-31 $3,465
2017-12-31 $3,540
2017-09-30 $3,400
2017-06-30 $3,380
2017-03-31 $3,390
2016-12-31 $3,345
2016-09-30 $3,311
2016-06-30 $2,896
2016-03-31 $3,134
2015-12-31 $3,141
2015-09-30 $3,091
2015-06-30 $3,164
2015-03-31 $3,126
2014-12-31 $2,925
2014-09-30 $2,848
2014-06-30 $2,890
2014-03-31 $2,837
2013-12-31 $2,715
2013-09-30 $2,575
2013-06-30 $2,536
2013-03-31 $2,611
2012-12-31 $2,531
2012-09-30 $2,467
2012-06-30 $2,279
2012-03-31 $2,348
2011-12-31 $2,310
2011-09-30 $2,198
2011-06-30 $2,197
2011-03-31 $2,133
2010-12-31 $1,874
2010-09-30 $1,792
2010-06-30 $1,765
2010-03-31 $1,787
2009-12-31 $1,565
2009-09-30 $1,711
2009-06-30 $1,761
2009-03-31 $1,646
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $12.399B $3.350B
Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $20.902B 7.10
BridgeBio Pharma (BBIO) United States $4.791B 0.00
Bausch Health Cos (BHC) Canada $3.597B 2.61
Amphastar Pharmaceuticals (AMPH) United States $2.469B 13.82
Supernus Pharmaceuticals (SUPN) United States $1.872B 377.44
Taysha Gene Therapies (TSHA) United States $0.314B 51.00
Personalis (PSNL) United States $0.270B 0.00
Assembly Biosciences (ASMB) United States $0.107B 0.00
Acasti Pharma (GRCE) Canada $0.031B 0.00
Sol-Gel Technologies (SLGL) Israel $0.014B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00